Clinical consequences of circulating CD28-negative T cells for solid organ transplantation

Transplant International

Volumn 29, Issue 3, 2016, Pages 274-284

  Betjes, Michiel G H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CD28; rejection; T cells; tolerance; transplantation

Indexed keywords

ABATACEPT; B7 ANTIGEN; BELATACEPT; CD134 ANTIGEN; CD137 ANTIGEN; CD2 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD57 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CX3CR1; EFALIZUMAB; INTERLEUKIN 15; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MYCOPHENOLATE MOFETIL; NATURAL KILLER CELL RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; STEROID; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ATHEROSCLEROSIS; AUTOIMMUNITY; BIOACCUMULATION; CARDIOVASCULAR RISK; CELL AGING; CELL DIFFERENTIATION; CELL DIVISION; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTION; EFFECTOR CELL; GRAFT REJECTION; HUMAN; LYMPHOCYTE FUNCTION; LYMPHOCYTIC INFILTRATION; MALIGNANT NEOPLASTIC DISEASE; MEMORY T LYMPHOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SUPPRESSOR CELL; T LYMPHOCYTE; AGE; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

AGE FACTORS; ANTIGENS, CD28; CYTOMEGALOVIRUS INFECTIONS; HUMANS; ORGAN TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION IMMUNOLOGY;

EID: 84958679242     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12658     Document Type: Review

References (120)

1. Shahinian A, Pfeffer K, Lee KP, et al,. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609.
2. Fagnoni FF, Vescovini R, Mazzola M, et al,. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 1996; 88: 501.
3. Pitcher CJ, Hagen SI, Walker JM, et al,. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168: 29.
4. Vallejo AN, Nestel AR, Schirmer M, Weyand CM, Goronzy JJ,. Aging-related deficiency of CD28 expression in CD4+ T cells is associated with the loss of gene-specific nuclear factor binding activity. J Biol Chem 1998; 273: 8119.
5. Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD,. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6: 876.
6. Schmitt N, Ueno H,. Regulation of human helper T cell subset differentiation by cytokines. Curr Opin Immunol 2015; 34: 130.
7. Betjes MG,. Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 2013; 9: 255.
8. Lotze MT, Zeh HJ, Rubartelli A, et al,. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007; 220: 60.
9. Acuto O, Michel F,. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003; 3: 939.
10. Acuto O, Mise-Omata S, Mangino G, Michel F,. Molecular modifiers of T cell antigen receptor triggering threshold: the mechanism of CD28 costimulatory receptor. Immunol Rev 2003; 192: 21.
11. Appay V, van Lier RA, Sallusto F, Roederer M,. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytometry A 2008; 73: 975.
12. Litjens NH, Huisman M, Baan CC, van Druningen CJ, Betjes MG,. Hepatitis B vaccine-specific CD4(+) T cells can be detected and characterised at the single cell level: limited usefulness of dendritic cells as signal enhancers. J Immunol Methods 2008; 330: 1.
13. Betjes MG, Meijers RW, de Wit EA, Weimar W, Litjens NH,. Terminally differentiated CD8+ Temra cells are associated with the risk for acute kidney allograft rejection. Transplantation 2012; 94: 63.
14. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA,. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006; 108: 3121.
15. Betjes MG, Huisman M, Weimar W, Litjens NH,. Expansion of cytolytic CD4+CD28- T cells in end-stage renal disease. Kidney Int 2008; 74: 760.
16. Betjes MG, Weimar W, Litjens NH,. CMV seropositivity determines epoetin dose and hemoglobin levels in patients with CKD. J Am Soc Nephrol 2009; 20: 2661.
17. Chiu WK, Fann M, Weng NP,. Generation and growth of CD28nullCD8+ memory T cells mediated by IL-15 and its induced cytokines. J Immunol 2006; 177: 7802.
18. Vallejo AN, Weyand CM, Goronzy JJ,. Functional disruption of the CD28 gene transcriptional initiator in senescent T cells. J Biol Chem 2001; 276: 2565.
19. Vallejo AN, Bryl E, Klarskov K, Naylor S, Weyand CM, Goronzy JJ,. Molecular basis for the loss of CD28 expression in senescent T cells. J Biol Chem 2002; 277: 46940.
20. Vallejo AN, Brandes JC, Weyand CM, Goronzy JJ,. Modulation of CD28 expression: distinct regulatory pathways during activation and replicative senescence. J Immunol 1999; 162: 6572.
21. Eck SC, Chang D, Wells AD, Turka LA,. Differential down-regulation of CD28 by B7-1 and B7-2 engagement. Transplantation 1997; 64: 1497.
22. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ,. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001; 167: 3231.
23. Lewis DE, Merched-Sauvage M, Goronzy JJ, Weyand CM, Vallejo AN,. Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T-cell receptor-independent inhibition of transcription. J Biol Chem 2004; 279: 29130.
24. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535.
25. Litjens NH, de Wit EA, Betjes MG,. Differential effects of age, cytomegalovirus-seropositivity and end-stage renal disease (ESRD) on circulating T lymphocyte subsets. Immun Ageing 2011; 8: 2.
26. Nikolich-Zugich J,. Aging of the T cell compartment in mice and humans: from no naive expectations to foggy memories. J Immunol 2014; 193: 2622.
27. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM,. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75: 12182.
28. Saurwein-Teissl M, Lung TL, Marx F, et al,. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002; 168: 5893.
29. Manfras BJ, Weidenbach H, Beckh KH, et al,. Oligoclonal CD8+ T-cell expansion in patients with chronic hepatitis C is associated with liver pathology and poor response to interferon-alpha therapy. J Clin Immunol 2004; 24: 258.
30. Komocsi A, Lamprecht P, Csernok E, et al,. Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. Am J Pathol 2002; 160: 1717.
31. Strioga M, Pasukoniene V, Characiejus D,. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 2011; 134: 17.
32. Meijers RW, Litjens NH, de Wit EA, et al,. Uremia causes premature ageing of the T cell compartment in end-stage renal disease patients. Immun Ageing 2012; 9: 19.
33. Meijers RW, Litjens NH, de Wit EA, et al,. Cytomegalovirus contributes partly to uremia-associated premature immunological ageing of the T-cell compartment. Clin Exp Immunol 2013; 174: 424.
34. Litjens NH, van Druningen CJ, Betjes MG,. Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 2006; 118: 83.
35. Betjes MG, Litjens NH, Zietse R,. Seropositivity for cytomegalovirus in patients with end-stage renal disease is strongly associated with atherosclerotic disease. Nephrol Dial Transplant 2007; 22: 3298.
36. Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH,. Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int 2011; 80: 208.
37. Focosi D, Bestagno M, Burrone O, Petrini M,. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 2010; 87: 107.
38. Brenchley JM, Karandikar NJ, Betts MR, et al,. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101: 2711.
39. Campisi J, d'Adda di Fagagna F,. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8: 729.
40. Rodier F, Campisi J,. Four faces of cellular senescence. J Cell Biol 2011; 192: 547.
41. Chong LK, Aicheler RJ, Llewellyn-Lacey S, Tomasec P, Brennan P, Wang EC,. Proliferation and interleukin 5 production by CD8hi CD57+ T cells. Eur J Immunol 2008; 38: 995.
42. Henson SM, Franzese O, Macaulay R, et al,. KLRG1 signaling induces defective Akt (ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 2009; 113: 6619.
43. Filaci G, Fenoglio D, Fravega M, et al,. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol 2007; 179: 4323.
44. Betjes MG, Meijers RW, de Wit LE, Litjens NH,. A killer on the road: circulating CD4(+)CD28null T cells as cardiovascular risk factor in ESRD patients. J Nephrol 2012; 25: 183.
45. Maly K, Schirmer M,. The story of CD4+ CD28- T cells revisited: solved or still ongoing? J Immunol Res 2015; 2015: 348746.
46. Wang F, Chen L, Shen Q, et al,. Characterization and clinical relevance of circulating CD4+CD28- T cells in Graves' disease. Immunol Lett 2015; 165: 47.
47. Yarde DN, Lorenzo-Arteaga K, Corley KP, Cabrera M, Sarvetnick NE,. CD28(-) CD8(+) T cells are significantly reduced and correlate with disease duration in juveniles with type 1 diabetes. Hum Immunol 2014; 75: 1069.
48. Mikulkova Z, Praksova P, Stourac P, et al,. Numerical defects in CD8+CD28- T-suppressor lymphocyte population in patients with type 1 diabetes mellitus and multiple sclerosis. Cell Immunol 2010; 262: 75.
49. Tulunay A, Yavuz S, Direskeneli H, Eksioglu-Demiralp E,. CD8+CD28-, suppressive T cells in systemic lupus erythematosus. Lupus 2008; 17: 630.
50. Reinke S, Geissler S, Taylor WR, et al,. Terminally differentiated CD8(+) T cells negatively affect bone regeneration in humans. Sci Transl Med 2013; 5: 177ra36.
51. Kumar G, Roger PM, Ticchioni M, et al,. T cells from chronic bone infection show reduced proliferation and a high proportion of CD28(-) CD4 T cells. Clin Exp Immunol 2014; 176: 49.
52. van Leeuwen EM, Remmerswaal EB, Vossen MT, et al,. Emergence of a CD4+CD28- granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173: 1834.
53. Bryl E, Vallejo AN, Matteson EL, Witkowski JM, Weyand CM, Goronzy JJ,. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 2005; 52: 2996.
54. Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ,. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood 2003; 101: 3543.
55. Meijers RW, Litjens NH, de Wit EA, Langerak AW, Baan CC, Betjes MG,. Uremia-associated immunological aging is stably imprinted in the T-cell system and not reversed by kidney transplantation. Transpl Int 2014; 27: 1272.
56. Dumitriu IE, Araguas ET, Baboonian C, Kaski JC,. CD4+ CD28 null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res 2009; 81: 11.
57. van de Berg PJ, van Leeuwen EM, ten Berge IJ, van Lier R,. Cytotoxic human CD4(+) T cells. Curr Opin Immunol 2008; 20: 339.
58. Sato K, Niessner A, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM,. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J Exp Med 2006; 203: 239.
59. Alonso-Arias R, Moro-Garcia MA, Vidal-Castineira JR, et al,. IL-15 preferentially enhances functional properties and antigen-specific responses of CD4+CD28(null) compared to CD4+CD28+ T cells. Aging Cell 2011; 10: 844.
60. Echeverria A, Moro-Garcia MA, Asensi V, Carton JA, Lopez-Larrea C, Alonso-Arias R,. CD4+CD28null T lymphocytes resemble CD8+CD28null T lymphocytes in their responses to IL-15 and IL-21 in HIV-infected patients. J Leukoc Biol 2015; jlb.1A0514-276RR. [Epub ahead of print].
61. Traitanon O, Gorbachev A, Bechtel JJ, et al,. IL-15 induces alloreactive CD28(-) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation. Am J Transplant 2014; 14: 1277.
62. Appay V, Bosio A, Lokan S, et al,. Sensitive gene expression profiling of human T cell subsets reveals parallel post-thymic differentiation for CD4+ and CD8+ lineages. J Immunol 2007; 179: 7406.
63. Engela AU, Baan CC, Litjens NH, et al,. Mesenchymal stem cells control alloreactive CD8(+) CD28(-) T cells. Clin Exp Immunol 2013; 174: 449.
64. Lo DJ, Weaver TA, Stempora L, et al,. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011; 11: 22.
65. Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR,. New insights in CD28-independent allograft rejection. Am J Transplant 2007; 7: 1917.
66. Litjens NH, de Wit EA, Baan CC, Betjes MG,. Activation-induced CD137 is a fast assay for identification and multi-parameter flow-cytometric analysis of alloreactive T cells. Clin Exp Immunol 2013; 174: 179.
67. Pavlakis M, Strehlau J, Lipman M, Shapiro M, Maslinski W, Strom TB,. Intragraft IL-15 transcripts are increased in human renal allograft rejection. Transplantation 1996; 62: 543.
68. Koulmanda M, Qipo A, Fan Z, et al,. Prolonged survival of allogeneic islets in cynomolgus monkeys after short-term triple therapy. Am J Transplant 2012; 12: 1296.
69. Ferrari-Lacraz S, Zheng XX, Kim YS, et al,. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001; 167: 3478.
70. Khan N, Shariff N, Cobbold M, et al,. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 2002; 169: 1984.
71. Weinberger B, Welzl K, Herndler-Brandstetter D, Parson W, Grubeck-Loebenstein B,. CD28(-)CD8(+) T cells do not contain unique clonotypes and are therefore dispensable. Immunol Lett 2009; 127: 27.
72. Mou D, Espinosa JE, Stempora L, Iwakoshi NN, Kirk AD,. Viral-induced CD28 loss evokes costimulation independent alloimmunity. J Surg Res 2015; 196: 241.
73. D'Orsogna LJ, van Besouw NM, van der Meer-Prins EM, et al,. Vaccine-induced allo-HLA-reactive memory T cells in a kidney transplantation candidate. Transplantation 2011; 91: 645.
74. Zhai Y, Wang Y, Wu Z, Kupiec-Weglinski JW,. Defective alloreactive CD8 T cell function and memory response in allograft recipients in the absence of CD4 help. J Immunol 2007; 179: 4529.
75. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP,. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852.
76. Ford ML, Wagener ME, Hanna SS, Pearson TC, Kirk AD, Larsen CP,. A critical precursor frequency of donor-reactive CD4+ T cell help is required for CD8+ T cell-mediated CD28/CD154-independent rejection. J Immunol 2008; 180: 7203.
77. Boleslawski E, BenOthman S, Grabar S, et al,. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transplant 2008; 22: 494.
78. Lin YX, Wang LL, Yan LN, et al,. Analysis of CD8+CD28- T-suppressor cells in living donor liver transplant recipients. Hepatobiliary Pancreat Dis Int 2009; 8: 241.
79. Colovai AI, Mirza M, Vlad G, et al,. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum Immunol 2003; 64: 31.
80. Cortesini R, LeMaoult J, Ciubotariu R, Cortesini NS,. CD8+CD28- T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity. Immunol Rev 2001; 182: 201.
81. Filaci G, Fravega M, Negrini S, et al,. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 2004; 65: 142.
82. Najafian N, Chitnis T, Salama AD, et al,. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest 2003; 112: 1037.
83. Suzuki M, Konya C, Goronzy JJ, Weyand CM,. Inhibitory CD8+ T cells in autoimmune disease. Hum Immunol 2008; 69: 781.
84. Sindhi R, Manavalan JS, Magill A, Suciu-Foca N, Zeevi A,. Reduced immunosuppression in pediatric liver-intestine transplant recipients with CD8+CD28- T-suppressor cells. Hum Immunol 2005; 66: 252.
85. Suciu-Foca N, Manavalan JS, Scotto L, et al,. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 2005; 5: 7.
86. Vlad G, Cortesini R, Suciu-Foca N,. License to heal: bidirectional interaction of antigen-specific regulatory T cells and tolerogenic APC. J Immunol 2005; 174: 5907.
87. Vlad G, King J, Chang CC, et al,. Gene profile analysis of CD8(+) ILT3-Fc induced T suppressor cells. Hum Immunol 2011; 72: 107.
88. Chaput N, Louafi S, Bardier A, et al,. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58: 520.
89. Manavalan JS, Kim-Schulze S, Scotto L, et al,. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 2004; 16: 1055.
90. Fenoglio D, Ferrera F, Fravega M, et al,. Advancements on phenotypic and functional characterization of non-antigen-specific CD8+CD28- regulatory T cells. Hum Immunol 2008; 69: 745.
91. Baeten D, Louis S, Braud C, et al,. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J Am Soc Nephrol 2006; 17: 294.
92. Yap M, Boeffard F, Clave E, et al,. Expansion of highly differentiated cytotoxic terminally differentiated effector memory CD8+ T cells in a subset of clinically stable kidney transplant recipients: a potential marker for late graft dysfunction. J Am Soc Nephrol 2014; 25: 1856.
93. Betjes MG, de Wit EE, Weimar W, Litjens NH,. Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrol Dial Transplant 2010; 25: 3640.
94. Betjes MG, Weimar W, Litjens NH,. Circulating CD4(+)CD28null T Cells May Increase the Risk of an Atherosclerotic Vascular Event Shortly after Kidney Transplantation. J Transplant 2013; 2013: 841430.
95. Litjens NH, van de Wetering J, van Besouw NM, Betjes MG,. The human alloreactive CD4+ T-cell repertoire is biased to a Th17 response and the frequency is inversely related to the number of HLA class II mismatches. Blood 2009; 114: 3947.
96. Trzonkowski P, Zilvetti M, Friend P, Wood KJ,. Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression. Transplantation 2006; 82: 1342.
97. Pearl JP, Parris J, Hale DA, et al,. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
98. Meijers RW, Betjes MG, Baan CC, Litjens NH,. T-cell ageing in end-stage renal disease patients: assessment and clinical relevance. World J Nephrol 2014; 3: 268.
99. Trzonkowski P, Debska-Slizien A, Jankowska M, et al,. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech Ageing Dev 2010; 131: 96.
100. Demmers MW, Baan CC, Janssen M, et al,. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. Transplantation 2014; 97: 47.
101. Suarez-Alvarez B, Lopez-Vazquez A, Baltar JM, Ortega F, Lopez-Larrea C,. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant 2009; 9: 251.
102. Pegram HJ, Andrews DM, Smyth MJ, Darcy PK, Kershaw MH,. Activating and inhibitory receptors of natural killer cells. Immunol Cell Biol 2011; 89: 216.
103. Thorp EB, Stehlik C, Ansari MJ,. T-cell exhaustion in allograft rejection and tolerance. Curr Opin Organ Transplant 2015; 20: 37.
104. Liu D, Krummey SM, Badell IR, et al,. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J Exp Med 2014; 211: 297.
105. Kinnear G, Jones ND, Wood KJ,. Costimulation blockade: current perspectives and implications for therapy. Transplantation 2013; 95: 527.
106. Esposito P, Grosjean F, Rampino T, et al,. Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities. Int Rev Immunol 2014; 33: 212.
107. Krummey SM, Ford ML,. New insights into T-cell cosignaling in allograft rejection and survival. Curr Opin Organ Transplant 2015; 20: 43.
108. Betjes MG, Tuk CW, Struijk DG, et al,. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993; 43: 641.
109. Weyand CM, Brandes JC, Schmidt D, Fulbright JW, Goronzy JJ,. Functional properties of CD4+ CD28- T cells in the aging immune system. Mech Ageing Dev 1998; 102: 131.
110. Zhai Y, Meng L, Gao F, Busuttil RW, Kupiec-Weglinski JW,. Allograft rejection by primed/memory CD8+ T cells is CD154 blockade resistant: therapeutic implications for sensitized transplant recipients. J Immunol 2002; 169: 4667.
111. Hodge G, Hodge S, Reynolds PN, Holmes M,. Targeting peripheral blood pro-inflammatory CD28null T cells and natural killer T-like cells by inhibiting CD137 expression: possible relevance to treatment of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2013; 32: 1081.
112. Hodge G, Mukaro V, Reynolds PN, Hodge S,. Role of increased CD8/CD28(null) T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease. Clin Exp Immunol 2011; 166: 94.
113. Dumitriu IE, Baruah P, Finlayson CJ, et al,. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circ Res 2012; 110: 857.
114. Leitner J, Herndler-Brandstetter D, Zlabinger GJ, Grubeck-Loebenstein B, Steinberger P,. CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28-CD8+ T Cells. J Immunol 2015; 195: 477.
115. Lee S, Yamada Y, Tonsho M, et al,. Alefacept promotes immunosuppression-free renal allograft survival in nonhuman primates via depletion of recipient memory T cells. Am J Transplant 2013; 13: 3223.
116. Page EK, Page AJ, Kwun J, et al,. Enhanced de novo alloantibody and antibody-mediated injury in rhesus macaques. Am J Transplant 2012; 12: 2395.
117. Weaver TA, Charafeddine AH, Agarwal A, et al,. Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. Nat Med 2009; 15: 746.
118. Lowe MC, Badell IR, Turner AP, et al,. Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. Am J Transplant 2013; 13: 312.
119. Ford ML, Adams AB, Pearson TC,. Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol 2014; 10: 14.
120. Schwarz C, Mayerhoffer S, Berlakovich GA, et al,. Long-term outcome of belatacept therapy in de novo kidney transplant recipients-a case-match analysis. Transpl Int 2015; 28: 820.